Bioventus Inc. Shareholder News: Johnson Fistel Encourages BVS Shareholders with Losses to Contact the Firm Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased Bioventus common stock? If you purchased Bioventus common stock and suffered significant losses on your investment, join our investigation now:
Or for more information, contact Jim Baker at email@example.com or (619) 814-4471
There is no cost or obligation to you.
What is Johnson Fistel investigating? On February 4, 2021, Bioventus conducted its initial public offering (“IPO”), and the company sold 8 million shares priced at $13.00 per share. Since the IPO the stock has plummeted to $3.26 as of November 8, 2022.
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or firstname.lastname@example.org.
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471